Effectiveness of Compression Therapy for the Prevention of Taxane-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.

IF 3.1 3区 医学 Q2 CLINICAL NEUROLOGY
Journal of Pain Research Pub Date : 2026-09-28 eCollection Date: 2026-01-01 DOI:10.2147/JPR.S621888
Nana Jiao, Hailing Ren, Feifei Yang, Jingping Wu, Yingjie Sun, Yang Li, Chenyang Wang
{"title":"Effectiveness of Compression Therapy for the Prevention of Taxane-Induced Peripheral Neuropathy: A Systematic Review and Meta-Analysis.","authors":"Nana Jiao, Hailing Ren, Feifei Yang, Jingping Wu, Yingjie Sun, Yang Li, Chenyang Wang","doi":"10.2147/JPR.S621888","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prophylactic efficacy of compression therapy for taxane-induced peripheral neuropathy (TIPN).</p><p><strong>Methods: </strong>Systematically searched Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, Wan Fang, CBM, and VIP databases from inception to January 30, 2026. Included Randomized clinical trial (RCT) and quasi-Randomized clinical trials (quasi-RCTs). Two investigators independently screened studies, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool (RoB 1.0) for RCTs and the Joanna Briggs Institute (JBI) critical appraisal checklist for quasi-RCTs. Data were analyzed using Rev Man version 5.3, with subgroup analyses conducted according to study design, chemotherapy regimen, compression modality, and chemotherapy cycles.</p><p><strong>Results: </strong>Eleven studies were included, comprising six RCTs and five quasi-RCTs and involving a total of 737 patients. Compression therapy reduced overall TIPN incidence (RR=0.63, 95% CI: 0.47-0.83) and the incidence of CTCAE grade ≥2 and PNQ grade ≥D sensory and motor neuropathy. The single quasi-RCT assessing overall TIPN also reported a lower incidence with compression therapy (1/94 vs 10/94). Among the quasi-RCTs, compression therapy reduced CTCAE grade ≥2 motor neuropathy (RR=0.56, 95% CI: 0.35-0.89), whereas the sensory and PNQ outcomes were not statistically significant. CIPNAT scores were lower with compression therapy (MD=-34.72, 95% CI: -52.16 to -17.29). No subgroup differences were found by chemotherapy regimen, compression modality, or number of chemotherapy cycles. Compression therapy was generally well tolerated.</p><p><strong>Conclusion: </strong>Compression therapy may reduce the incidence of TIPN, but the findings should be interpreted cautiously because of the inclusion of quasi-RCTs, limited blinding, and heterogeneity in outcome measures. Further well-designed randomized controlled trials are needed to confirm these findings.</p>","PeriodicalId":16661,"journal":{"name":"Journal of Pain Research","volume":"19 ","pages":"621888"},"PeriodicalIF":3.1000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13632629/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pain Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JPR.S621888","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: To evaluate the prophylactic efficacy of compression therapy for taxane-induced peripheral neuropathy (TIPN).

Methods: Systematically searched Cochrane Library, PubMed, EMBASE, Web of Science, CNKI, Wan Fang, CBM, and VIP databases from inception to January 30, 2026. Included Randomized clinical trial (RCT) and quasi-Randomized clinical trials (quasi-RCTs). Two investigators independently screened studies, extracted data, and assessed the risk of bias using the Cochrane risk of bias tool (RoB 1.0) for RCTs and the Joanna Briggs Institute (JBI) critical appraisal checklist for quasi-RCTs. Data were analyzed using Rev Man version 5.3, with subgroup analyses conducted according to study design, chemotherapy regimen, compression modality, and chemotherapy cycles.

Results: Eleven studies were included, comprising six RCTs and five quasi-RCTs and involving a total of 737 patients. Compression therapy reduced overall TIPN incidence (RR=0.63, 95% CI: 0.47-0.83) and the incidence of CTCAE grade ≥2 and PNQ grade ≥D sensory and motor neuropathy. The single quasi-RCT assessing overall TIPN also reported a lower incidence with compression therapy (1/94 vs 10/94). Among the quasi-RCTs, compression therapy reduced CTCAE grade ≥2 motor neuropathy (RR=0.56, 95% CI: 0.35-0.89), whereas the sensory and PNQ outcomes were not statistically significant. CIPNAT scores were lower with compression therapy (MD=-34.72, 95% CI: -52.16 to -17.29). No subgroup differences were found by chemotherapy regimen, compression modality, or number of chemotherapy cycles. Compression therapy was generally well tolerated.

Conclusion: Compression therapy may reduce the incidence of TIPN, but the findings should be interpreted cautiously because of the inclusion of quasi-RCTs, limited blinding, and heterogeneity in outcome measures. Further well-designed randomized controlled trials are needed to confirm these findings.

压迫疗法预防紫杉烷诱导的周围神经病变的有效性:一项系统综述和荟萃分析。
目的:评价加压治疗对紫杉烷性周围神经病变(TIPN)的预防作用。方法:系统检索Cochrane Library、PubMed、EMBASE、Web of Science、CNKI、万方、CBM、VIP等数据库,检索时间为建库至2026年1月30日。纳入随机临床试验(RCT)和准随机临床试验(准RCT)。两名研究者独立筛选研究,提取数据,并使用Cochrane随机对照试验的偏倚风险工具(RoB 1.0)和准随机对照试验的乔安娜布里格斯研究所(JBI)关键评估清单评估偏倚风险。使用Rev Man 5.3版本分析数据,根据研究设计、化疗方案、压缩方式和化疗周期进行亚组分析。结果:纳入11项研究,包括6项随机对照试验和5项准随机对照试验,共涉及737例患者。压缩治疗降低了总TIPN发生率(RR=0.63, 95% CI: 0.47-0.83)和CTCAE分级≥2级和PNQ分级≥D级感觉和运动神经病变的发生率。评估总体TIPN的单一准rct也报告了压迫治疗的发生率较低(1/94 vs 10/94)。在准随机对照试验中,压缩治疗减少了CTCAE≥2级运动神经病变(RR=0.56, 95% CI: 0.35-0.89),而感觉和PNQ结果无统计学意义。压缩治疗组CIPNAT评分较低(MD=-34.72, 95% CI: -52.16 ~ -17.29)。化疗方案、压迫方式或化疗周期数没有亚组差异。压迫治疗通常耐受性良好。结论:压迫治疗可能会降低TIPN的发生率,但由于纳入了准随机对照试验、有限盲法和结果测量的异质性,研究结果应谨慎解读。需要进一步精心设计的随机对照试验来证实这些发现。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Pain Research
Journal of Pain Research CLINICAL NEUROLOGY-
CiteScore
4.50
自引率
3.70%
发文量
411
审稿时长
16 weeks
期刊介绍: Journal of Pain Research is an international, peer-reviewed, open access journal that welcomes laboratory and clinical findings in the fields of pain research and the prevention and management of pain. Original research, reviews, symposium reports, hypothesis formation and commentaries are all considered for publication. Additionally, the journal now welcomes the submission of pain-policy-related editorials and commentaries, particularly in regard to ethical, regulatory, forensic, and other legal issues in pain medicine, and to the education of pain practitioners and researchers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书